作者: Huei Ng , Aiping Lu , Ge Lin , Ling Qin , Zhijun Yang
DOI: 10.3390/IJMS16010230
关键词: In vivo 、 Drug delivery 、 Chemistry 、 Targeted drug delivery 、 Pharmacology 、 Carbonic Anhydrase IX 、 Liposome 、 Nanocarriers 、 Cancer 、 Cancer cell
摘要: Drug delivery nanocarriers, especially targeted drug by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal enhanced efficacy, while simultaneously reducing side effects, owing to properties such more localization in tumors and active cellular uptake. Here, we highlight the features immunoliposomes distinguish them from previous anticancer therapies, describe how these provide potential therapeutic effects not achievable with other modalities. While large number studies has been published, emphasis here is placed on carbonic anhydrase IX (CA-IX) conjugated likely open new chapter system using deliver ingredients cancer cells vivo.